share_log

Novavax | DEFA14A: Others

Novavax | DEFA14A: Others

諾瓦瓦克斯醫藥 | DEFA14A：其他
美股sec公告 ·  06/05 06:06
Moomoo AI 已提取核心訊息
Novavax, Inc. has filed Amendment No. 1 to its Definitive Proxy Statement with the U.S. Securities and Exchange Commission on April 29, 2024, in preparation for its 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. This amendment specifically addresses and clarifies an immaterial aspect of the Amended and Restated 2015 Stock Incentive Plan related to 'Proposal 3 – Amendment and Restatement of the 2015 Stock Plan.' The amendment introduces new compensation limits for non-employee directors, setting a cap of $1,500,000 for the chairman and $1,000,000 for other non-employee directors, with an exception for the year in which a non-employee director begins their service on the Board. The amendment also removes the individual limits on awards granted under the 2015 Stock Plan, which previously restricted the number of shares for stock options, stock appreciation rights (SARs), and other stock awards. This filing does not affect any other items or information presented in the original 2024 Definitive Proxy Statement and should be read in conjunction with it.
Novavax, Inc. has filed Amendment No. 1 to its Definitive Proxy Statement with the U.S. Securities and Exchange Commission on April 29, 2024, in preparation for its 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. This amendment specifically addresses and clarifies an immaterial aspect of the Amended and Restated 2015 Stock Incentive Plan related to 'Proposal 3 – Amendment and Restatement of the 2015 Stock Plan.' The amendment introduces new compensation limits for non-employee directors, setting a cap of $1,500,000 for the chairman and $1,000,000 for other non-employee directors, with an exception for the year in which a non-employee director begins their service on the Board. The amendment also removes the individual limits on awards granted under the 2015 Stock Plan, which previously restricted the number of shares for stock options, stock appreciation rights (SARs), and other stock awards. This filing does not affect any other items or information presented in the original 2024 Definitive Proxy Statement and should be read in conjunction with it.
Novavax, Inc.於2024年4月29日向美國證券交易委員會提交了修改版的《明確授權代表議決權委託書》第一修訂版，以準備2024年6月13日舉行的股東週年大會。此修訂特別涉及和澄清了《2015年修訂之股票激勵計畫》（Amended and Restated 2015 Stock Incentive Plan）中一個不重要的方面，涉及“第3項 – 2015年股票計畫之修訂與改動”。該修訂引入了新的非員工董事報酬上限，設置主席的上限為150萬美元，其他非員工董事的上限為100萬美元，對於新加入董事會的非員工董事服務的年份有例外。修訂還取消了2015年股票計畫中關於授予獎項的個人限制，這些限制以前限制了股票期權、股票增值權（SAR）和其他股票獎勵的股票數量。此提交與原本2024年的明確授權代表議決權委託書中呈獻的任何其他項目或信息無關，應該與該明確授權代表議決權委託書一同閱讀。
Novavax, Inc.於2024年4月29日向美國證券交易委員會提交了修改版的《明確授權代表議決權委託書》第一修訂版，以準備2024年6月13日舉行的股東週年大會。此修訂特別涉及和澄清了《2015年修訂之股票激勵計畫》（Amended and Restated 2015 Stock Incentive Plan）中一個不重要的方面，涉及“第3項 – 2015年股票計畫之修訂與改動”。該修訂引入了新的非員工董事報酬上限，設置主席的上限為150萬美元，其他非員工董事的上限為100萬美元，對於新加入董事會的非員工董事服務的年份有例外。修訂還取消了2015年股票計畫中關於授予獎項的個人限制，這些限制以前限制了股票期權、股票增值權（SAR）和其他股票獎勵的股票數量。此提交與原本2024年的明確授權代表議決權委託書中呈獻的任何其他項目或信息無關，應該與該明確授權代表議決權委託書一同閱讀。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息